Cazzola, M. Myelodysplastic syndromes. N. Engl. J. Med. 383, 1358–1374 (2020). This review article discusses definitions, pathophysiology, diagnosis, risk stratification and therapy of MDS.
Article CAS PubMed Google Scholar
Bejar, R., Levine, R. & Ebert, B. L. Unraveling the molecular pathophysiology of myelodysplastic syndromes. J. Clin. Oncol. 29, 504–515 (2011).
Article CAS PubMed PubMed Central Google Scholar
Giagounidis, A. & Haase, D. Morphology, cytogenetics and classification of MDS. Best Pract. Res. Clin. Haematol. 26, 337–353 (2013).
Article CAS PubMed Google Scholar
Ma, X. Epidemiology of myelodysplastic syndromes. Am. J. Med. 125 (Suppl. 7), S2–S5 (2012). This review article discusses the epidemiology of MDS.
Article PubMed PubMed Central Google Scholar
National Cancer Institute. SEER Cancer Statistics Review, 1975-2016. Myelodysplastic Syndromes (MDS), Chronic Myeloproliferative Disorders (CMD), and Chronic Myelomonocytic Leukemia (CMML). National Cancer Institute http://seer.cancer.gov/csr/1975_2016/browse_csr.php?sectionSEL=30&pageSEL=sect_30_intro.01.html (2022).
Offman, J. et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 104, 822–828 (2004).
Article CAS PubMed Google Scholar
Garcia-Manero, G., Chien, K. S. & Montalban-Bravo, G. Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. Am. J. Hematol. 95, 1399–1420 (2020).
Goldberg, S. L. et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J. Clin. Oncol. 28, 2847–2852 (2010).
Rollison, D. E. et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 112, 45–52 (2008).
Article CAS PubMed Google Scholar
Steensma, D. P. The changing classification of myelodysplastic syndromes: what’s in a name? Hematol. Am. Soc. Hematol. Educ. Program https://doi.org/10.1182/asheducation-2009.1.645 (2009).
Khoury, J. D. et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 36, 1703–1719 (2022). This publication is the fifth edition of the WHO Classification of MDS.
Article PubMed PubMed Central Google Scholar
Valent, P. et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk. Res. 31, 727–736 (2007).
Estey, E., Hasserjian, R. P. & Dohner, H. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. Blood 139, 323–332 (2022). This article discusses how to distinguish MDS from AML.
Article CAS PubMed PubMed Central Google Scholar
Zeidan, A. M., Shallis, R. M., Wang, R., Davidoff, A. & Ma, X. Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it. Blood Rev. 34, 1–15 (2019).
Slack, J., Nguyen, L., Naugler, C. & Rashid-Kolvear, F. Incidence of myelodysplastic syndromes in a major Canadian metropolitan area. J. Appl. Lab. Med. 3, 378–383 (2018).
Maynadie, M. et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br. J. Cancer 74, 288–290 (1996).
Article CAS PubMed PubMed Central Google Scholar
Williamson, P. J., Kruger, A. R., Reynolds, P. J., Hamblin, T. J. & Oscier, D. G. Establishing the incidence of myelodysplastic syndrome. Br. J. Haematol. 87, 743–745 (1994).
Article CAS PubMed Google Scholar
Dinmohamed, A. G. et al. Trends in incidence, initial treatment and survival of myelodysplastic syndromes: a population-based study of 5144 patients diagnosed in the Netherlands from 2001 to 2010. Eur. J. Cancer 50, 1004–1012 (2014).
Gattermann, N. et al. Myelodysplastic syndromes: aspects of current medical care and economic considerations in Germany. Onkologie 31, 477–484 (2008).
Bonadies, N. et al. Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012. Cancer Epidemiol. 46, 85–92 (2017).
Avgerinou, C. et al. The incidence of myelodysplastic syndromes in Western Greece is increasing. Ann. Hematol. 92, 877–887 (2013).
Article PubMed PubMed Central Google Scholar
Moreno Berggren, D. et al. Prognostic scoring systems for myelodysplastic syndromes (MDS) in a population-based setting: a report from the Swedish MDS register. Br. J. Haematol. 181, 614–627 (2018).
Iglesias Gallego, M. et al. Incidence and characteristics of myelodysplastic syndromes in Ourense (Spain) between 1994–1998. Haematologica 88, 1197–1199 (2003).
Gologan, R. Demo-geographical data of myelodysplastic syndrome based on a large sample of patients from a Romanian Hematological Center. J. BUON 15, 547–555 (2010).
Semochkin, S., Tolstykh, T., Dudina, G. & Fink, O. Clinical and epidemiological characteristics of myelodysplastic syndromes in adults [Russian]. Georgian Med. News 252, 108–115 (2016).
Wang, W., Wang, H., Wang, X. Q. & Lin, G. W. First report of incidence of adult myelodysplastic syndrome in China. Ann. Hematol. 91, 1321–1322 (2012).
Park, E. H. et al. Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012. Blood Res. 50, 204–217 (2015).
Article PubMed PubMed Central Google Scholar
Chihara, D. et al. Incidence of myelodysplastic syndrome in Japan. J. Epidemiol. 24, 469–473 (2014).
Rodger, E. J. & Morison, I. M. Myelodysplastic syndrome in New Zealand and Australia. Intern. Med. J. 42, 1235–1242 (2012).
Article CAS PubMed Google Scholar
Otrock, Z. K. et al. A nationwide non-interventional epidemiological data registry on myelodysplastic syndromes in Lebanon. Am. J. Blood Res. 5, 86–90 (2015).
PubMed PubMed Central Google Scholar
Feliciano, S. V. M. et al. Incidence and mortality of myeloid malignancies in children, adolescents and young adults in Brazil: a population-based study. Cancer Epidemiol. 62, 101583 (2019).
Velez, A. et al. Incidence of myelodysplastic syndromes from a medical care program in Buenos Aires, Argentina. Clin. Lymphoma Myeloma Leuk. 19 (Suppl. 1), S346 (2019).
Ma, X., Does, M., Raza, A. & Mayne, S. T. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 109, 1536–1542 (2007).
Cronin, K. A., Ries, L. A. & Edwards, B. K. The surveillance, epidemiology, and end results (SEER) program of the National Cancer Institute. Cancer 120 (Suppl. 23), 3755–3757 (2014).
Craig, B. M., Rollison, D. E., List, A. F. & Cogle, C. R. Underreporting of myeloid malignancies by United States cancer registries. Cancer Epidemiol. Biomark. Prev. 21, 474–481 (2012).
Cogle, C. R., Craig, B. M., Rollison, D. E. & List, A. F. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 117, 7121–7125 (2011).
Article CAS PubMed PubMed Central Google Scholar
Cogle, C. R. et al. High rate of uncaptured myelodysplastic syndrome cases and an improved method of case ascertainment. Leuk. Res. 38, 71–75 (2014).
Sant, M. et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 116, 3724–3734 (2010).
Article CAS PubMed Google Scholar
Cogle, C. R. Incidence and burden of the myelodysplastic syndromes. Curr. Hematol. Malig. Rep. 10, 272–281 (2015).
Article PubMed PubMed Central Google Scholar
Niemeyer, C. M. & Baumann, I. Myelodysplastic syndrome in children and adolescents. Semin. Hematol. 45, 60–70 (2008).
Article CAS PubMed Google Scholar
Mian, S. A. & Bonnet, D. Nature or nurture? Role of the bone marrow microenvironment in the genesis and maintenance of Myelodysplastic syndromes. Cancers https://doi.org/10.3390/cancers13164116 (2021).
留言 (0)